MACROGENICS INCMGNXEarnings & Financial Report
MacroGenics Inc is a clinical-stage biopharmaceutical firm specializing in the research and development of novel immunotherapies for cancer and autoimmune disorders. Its core product pipeline centers on monoclonal antibody-based treatments, with key programs targeting solid tumors and hematological malignancies, supported by partnerships with global pharmaceutical partners.
MGNX Q4 FY2025 Key Financial Metrics
Revenue
$41.2M
Gross Profit
N/A
Operating Profit
$-12.1M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
-29.3%
Net Margin
N/A
YoY Growth
113.0%
EPS
$-0.23
MACROGENICS INC Q4 FY2025 Financial Summary
MACROGENICS INC reported revenue of $41.2M (up 113.0% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $41.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | -29.3% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
MACROGENICS INC Q4 FY2025 revenue of $41.2M breaks down across 3 segments, led by Revenue From Collaborative Agreements at $20.3M (49.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Revenue From Collaborative Agreements | $20.3M | 49.2% |
| Contract Manufacturing | $11.3M | 27.3% |
| Other | $9.7M | 23.5% |
MACROGENICS INC Revenue by Segment — Quarterly Trend
MACROGENICS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Revenue From Collaborative Agreements and Contract Manufacturing) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Revenue From Collaborative Agreements | $20.3M | $53.0M | $6.9M | — |
| Contract Manufacturing | $11.3M | $19.8M | $15.4M | — |
| Other | $9.7M | — | — | — |
MACROGENICS INC Annual Revenue by Year
MACROGENICS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $149.5M).
MACROGENICS INC Quarterly Revenue & Net Profit History
MACROGENICS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $41.2M | +113.0% | N/A | N/A |
| Q3 FY2025 | $72.8M | -34.2% | $16.8M | 23.1% |
| Q2 FY2025 | $22.2M | +106.0% | $-36.3M | -163.0% |
| Q1 FY2025 | $13.2M | +44.9% | $-41.0M | -311.1% |
| Q4 FY2024 | $19.4M | +80.5% | N/A | N/A |
| Q3 FY2024 | $110.7M | +964.8% | $56.3M | 50.9% |
| Q2 FY2024 | $10.8M | -17.8% | $-55.7M | -515.6% |
| Q1 FY2024 | $9.1M | -62.8% | $-52.2M | -573.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $10.8M | $110.7M | $19.4M | $13.2M | $22.2M | $72.8M | $41.2M |
| YoY Growth | -62.8% | -17.8% | 964.8% | 80.5% | 44.9% | 106.0% | -34.2% | 113.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $248.3M | $201.1M | $264.5M | $261.7M | $224.6M | $245.4M | $270.8M | $256.8M |
| Liabilities | $142.1M | $143.3M | $144.4M | $145.6M | $145.4M | $198.8M | $203.8M | $201.3M |
| Equity | $106.2M | $57.8M | $120.1M | $116.1M | $79.1M | $46.6M | $67.0M | $55.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-45.6M | $-44.5M | $60.2M | $-38.4M | $-46.9M | $-47.0M | $-30.2M | $43.0M |